XML 75 R44.htm IDEA: XBRL DOCUMENT v3.26.1
Financial assets and liabilities (Tables)
12 Months Ended
Dec. 31, 2025
Fair Value Measurement [Abstract]  
Disclosure of carrying amounts and fair value of financial assets The following table shows the carrying amounts and fair value of financial assets and financial liabilities, including their
levels in the fair value hierarchy.
Tax and employee-related payables are non-financial liabilities and are therefore excluded from the tables below. They are
presented in Note 17.2.
AS OF
DECEMBER 31, 2023
(amounts in thousands of euros)
AMOUNT
RECOGNIZED
IN THE
STATEMENT
OF FINANCIAL
POSITION
FAIR VALUE
ASSETS/
LIABILITIES
AT FAIR
VALUE
THROUGH
PROFIT AND
LOSS
ASSETS AT
AMORTIZED
COST
LIABILITIES
AT AMORTIZED
COST
Other financial assets (2)
22,055
22,394
22,394
Other receivables and assets (2)
27,164
27,164
27,164
Cash and cash equivalents (1)
251,942
251,942
251,942
Total financial assets
301,161
301,500
301,500
Financial liabilities—non-current portion (4, Note 15)
39,697
40,622
18,506
42,768
Financial liabilities—current portion (3, Note 15)
37,348
37,348
11,531
5,165
Trade payables and other current liabilities (3)
47,221
47,221
47,221
Total financial liabilities
124,266
125,191
30,037
95,154
AS OF
DECEMBER 31, 2024
(amounts in thousands of euros)
AMOUNT
RECOGNIZED
IN THE
STATEMENT
OF FINANCIAL
POSITION
FAIR VALUE
ASSETS/
LIABILITIES
AT FAIR
VALUE
THROUGH
PROFIT AND
LOSS
ASSETS AT
AMORTIZED
COST
LIABILITIES
AT AMORTIZED
COST
Other financial assets (2)
13,473
12,690
12,690
Other receivables and assets (2)
19,843
19,843
19,843
Cash and cash equivalents (1)
144,221
144,221
144,221
Total financial assets
177,537
176,754
176,754
Financial liabilities—non-current portion (4, Note 15)
69,069
73,497
3,620
69,877
Financial liabilities—current portion (3, Note 15)
44,935
44,935
21,183
23,752
Trade payables and other current liabilities (3)
43,824
43,824
43,824
Total financial liabilities
157,828
162,256
24,803
137,453
AS OF
DECEMBER 31, 2025
(amounts in thousands of euros)
AMOUNT
RECOGNIZED
IN THE
STATEMENT
OF FINANCIAL
POSITION
FAIR VALUE
ASSETS/
LIABILITIES
AT FAIR
VALUE
THROUGH
PROFIT AND
LOSS
ASSETS AT
AMORTIZED
COST
LIABILITIES
AT AMORTIZED
COST
Other financial assets (2)
26,772
27,141
27,141
Other receivables and assets (2)
13,769
13,769
13,769
Cash and cash equivalents (1)
516,685
516,685
437,031
79,654
Total financial assets
557,226
557,595
437,031
120,565
Financial liabilities—non-current portion (4, Note 15)
30,790
102,555
102,555
Financial liabilities—current portion (3, Note 15)
1,302
1,302
1,302
Trade payables and other current liabilities (3)
37,552
37,552
37,552
Total financial liabilities
69,644
141,409
141,409
(1)    The fair value of cash and cash equivalents is determined based on Level 1 fair value measurement and corresponds to the
market value of the assets.
(2)    The carrying amount of financial assets measured at amortized cost is deemed to be a reasonable estimate of fair value, except
for the long-term advances made to CROs, whose fair value is determined based on Level 3 fair value measurement and is estimated
based on future cash-flows discounted at market rates, using credit spreads ranging from 104 bp to 218 bp as of December 31, 2023,
131 bp to 271 bp as of December 31, 2024 and 34 bp to 131 bp as of December 31, 2025. As of December 31, 2023, 2024, and 2025,
an increase in the credit spread by +100 bp would result in a decrease in the advances fair value by €23 thousand, €235 thousand, and
€231 thousand, respectively.
(3)    The carrying amount of short-term financial liabilities measured at amortized cost was deemed to be a reasonable estimate of
fair value.
(4)    The fair value of the royalty certificates, Heights convertible notes, Kreos / Claret BSA and Minimum Return Indemnifications
is based on Level 3 fair value measurement and is estimated based on models and assumptions detailed in Note 15. The fair value of
other long-term financial liabilities is determined based on Level 3 fair value measurement and is estimated based on future cash-flows
discounted at market rates, using the following assumptions:
For the debt components of the Kreos / Claret OCABSA (tranche A) and the tranches B and C of the Kreos / Claret straight
bond loans, a credit spread of 960 bp as of August 22, 2023, 900 bp as of December 31, 2023 and 750 bp as of December 31,
2024.
As of August 22, 2023, December 31, 2023 (tranche A) and December 31, 2024 (all three tranches), an increase in the credit
spread by +100 bp would result in a decrease in the Kreos / Claret debt components fair value by respectively €624 thousand
€538 thousand and €958 thousand.
For the conditional advances and the PGE loan, a credit spread of 900 bp as of December 31, 2023, and 730 bp as of
December 31, 2024. An increase in the credit spread by +100 bp would result in the following:
As of December 31, 2023, and 2024, a decrease in the PGE loan fair value by €39 thousand and €21 thousand
respectively.
As of December 31, 2023, a decrease in the RNP-VIR conditional advance fair value by €15 thousand.
As of December 31, 2023, a decrease in the CARENA conditional advance fair value by €37 thousand.
As of December 31, 2023, a decrease in the Ebola conditional advance fair value by €1 thousand.
Disclosure of carrying amounts and fair value of financial liabilities The following table shows the carrying amounts and fair value of financial assets and financial liabilities, including their
levels in the fair value hierarchy.
Tax and employee-related payables are non-financial liabilities and are therefore excluded from the tables below. They are
presented in Note 17.2.
AS OF
DECEMBER 31, 2023
(amounts in thousands of euros)
AMOUNT
RECOGNIZED
IN THE
STATEMENT
OF FINANCIAL
POSITION
FAIR VALUE
ASSETS/
LIABILITIES
AT FAIR
VALUE
THROUGH
PROFIT AND
LOSS
ASSETS AT
AMORTIZED
COST
LIABILITIES
AT AMORTIZED
COST
Other financial assets (2)
22,055
22,394
22,394
Other receivables and assets (2)
27,164
27,164
27,164
Cash and cash equivalents (1)
251,942
251,942
251,942
Total financial assets
301,161
301,500
301,500
Financial liabilities—non-current portion (4, Note 15)
39,697
40,622
18,506
42,768
Financial liabilities—current portion (3, Note 15)
37,348
37,348
11,531
5,165
Trade payables and other current liabilities (3)
47,221
47,221
47,221
Total financial liabilities
124,266
125,191
30,037
95,154
AS OF
DECEMBER 31, 2024
(amounts in thousands of euros)
AMOUNT
RECOGNIZED
IN THE
STATEMENT
OF FINANCIAL
POSITION
FAIR VALUE
ASSETS/
LIABILITIES
AT FAIR
VALUE
THROUGH
PROFIT AND
LOSS
ASSETS AT
AMORTIZED
COST
LIABILITIES
AT AMORTIZED
COST
Other financial assets (2)
13,473
12,690
12,690
Other receivables and assets (2)
19,843
19,843
19,843
Cash and cash equivalents (1)
144,221
144,221
144,221
Total financial assets
177,537
176,754
176,754
Financial liabilities—non-current portion (4, Note 15)
69,069
73,497
3,620
69,877
Financial liabilities—current portion (3, Note 15)
44,935
44,935
21,183
23,752
Trade payables and other current liabilities (3)
43,824
43,824
43,824
Total financial liabilities
157,828
162,256
24,803
137,453
AS OF
DECEMBER 31, 2025
(amounts in thousands of euros)
AMOUNT
RECOGNIZED
IN THE
STATEMENT
OF FINANCIAL
POSITION
FAIR VALUE
ASSETS/
LIABILITIES
AT FAIR
VALUE
THROUGH
PROFIT AND
LOSS
ASSETS AT
AMORTIZED
COST
LIABILITIES
AT AMORTIZED
COST
Other financial assets (2)
26,772
27,141
27,141
Other receivables and assets (2)
13,769
13,769
13,769
Cash and cash equivalents (1)
516,685
516,685
437,031
79,654
Total financial assets
557,226
557,595
437,031
120,565
Financial liabilities—non-current portion (4, Note 15)
30,790
102,555
102,555
Financial liabilities—current portion (3, Note 15)
1,302
1,302
1,302
Trade payables and other current liabilities (3)
37,552
37,552
37,552
Total financial liabilities
69,644
141,409
141,409
(1)    The fair value of cash and cash equivalents is determined based on Level 1 fair value measurement and corresponds to the
market value of the assets.
(2)    The carrying amount of financial assets measured at amortized cost is deemed to be a reasonable estimate of fair value, except
for the long-term advances made to CROs, whose fair value is determined based on Level 3 fair value measurement and is estimated
based on future cash-flows discounted at market rates, using credit spreads ranging from 104 bp to 218 bp as of December 31, 2023,
131 bp to 271 bp as of December 31, 2024 and 34 bp to 131 bp as of December 31, 2025. As of December 31, 2023, 2024, and 2025,
an increase in the credit spread by +100 bp would result in a decrease in the advances fair value by €23 thousand, €235 thousand, and
€231 thousand, respectively.
(3)    The carrying amount of short-term financial liabilities measured at amortized cost was deemed to be a reasonable estimate of
fair value.
(4)    The fair value of the royalty certificates, Heights convertible notes, Kreos / Claret BSA and Minimum Return Indemnifications
is based on Level 3 fair value measurement and is estimated based on models and assumptions detailed in Note 15. The fair value of
other long-term financial liabilities is determined based on Level 3 fair value measurement and is estimated based on future cash-flows
discounted at market rates, using the following assumptions:
For the debt components of the Kreos / Claret OCABSA (tranche A) and the tranches B and C of the Kreos / Claret straight
bond loans, a credit spread of 960 bp as of August 22, 2023, 900 bp as of December 31, 2023 and 750 bp as of December 31,
2024.
As of August 22, 2023, December 31, 2023 (tranche A) and December 31, 2024 (all three tranches), an increase in the credit
spread by +100 bp would result in a decrease in the Kreos / Claret debt components fair value by respectively €624 thousand
€538 thousand and €958 thousand.
For the conditional advances and the PGE loan, a credit spread of 900 bp as of December 31, 2023, and 730 bp as of
December 31, 2024. An increase in the credit spread by +100 bp would result in the following:
As of December 31, 2023, and 2024, a decrease in the PGE loan fair value by €39 thousand and €21 thousand
respectively.
As of December 31, 2023, a decrease in the RNP-VIR conditional advance fair value by €15 thousand.
As of December 31, 2023, a decrease in the CARENA conditional advance fair value by €37 thousand.
As of December 31, 2023, a decrease in the Ebola conditional advance fair value by €1 thousand.